Lumeda

What Lumeda does

Lumeda is a clinical-stage biotechnology company developing intraoperative photodynamic therapy (PDT) for the treatment of lung cancer. Founded in 2020 and headquartered in Rocky Hill, Connecticut, the company operates with a small team of 1-10 employees under CEO Alexander Zinke. The company's stated mission is to enable practical intraoperative PDT, a treatment approach in which light-activated drugs are administered during surgery to selectively destroy residual cancer cells. This targets a specific clinical application in lung cancer, where intraoperative adjuvant therapy could reduce local recurrence rates and improve surgical outcomes.

The company's core technology is intraoperative PDT applied to lung cancer treatment, a narrow indication within the broader photodynamic therapy market that was valued at $1.77 billion in 2023 and is projected to reach $3.43 billion by 2032 at a 7.7% CAGR, with North America holding 36.72% market share. No specific product, device platform, photosensitizing agent, or clinical trial results have been disclosed in the available data. The company website was inaccessible at the time of review, and no press materials, SEC filings, or patent disclosures were available to characterize the underlying technical architecture, dosing protocol, or device specifications.

Lumeda's business model has not been publicly articulated. The company has raised approximately $7.35 million across three funding rounds between February 2020 and April 2021, with Connecticut Innovations leading the $4.3 million round in April 2021 and Cycle Venture Partners participating. Investors in the earlier rounds are not disclosed. With no commercial products, no disclosed customers, no FDA approval status, and no announced go-to-market strategy, Lumeda is positioned as a pre-revenue, clinical-stage biotech likely pursuing a development-to-commercialization pathway typical of medical device and combination product companies, in which future revenue would derive from hospital and surgical center sales, licensing, or partnerships once regulatory clearance is obtained.

Name

Lumeda

Website

https://lumedainc.com

Company type

Private

Founded year

2020

Headcount range

1–10 employees

Short description

Lumeda is a clinical-stage biotechnology company developing intraoperative photodynamic therapy (PDT) for lung cancer treatment. Founded in 2020 and based in Rocky Hill, Connecticut, the company targets thoracic oncology with light-activated drug therapy applied during surgery.

Ownership category

akta.pro rank

Product category

Surgical Oncology Photodynamic Therapy Devices

NAICS

Scientific Research and Development Services (5417), Medical Equipment and Supplies Manufacturing (3391)

SIC

Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)

akta.pro secondary industry

Infrared Therapy (Infrared Sauna & Light Therapy) (HSADAKAG)

Keywords

• Intraoperative photodynamic therapy
• Lung cancer treatment
• Surgical oncology devices
• Biotechnology medical devices
• Light-activated therapy

Headquarters

HQ city

Rocky Hill

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Lumeda develops intraoperative photodynamic therapy (PDT) technology for treating lung cancer. The company's platform enables clinicians to apply light-activated therapeutic agents during surgery to selectively target malignant tissue. The offering is positioned as a practical PDT solution designed for integration into thoracic surgical workflows.

Differentiator

Problem solved

Functional benefit

Products and services

• Intraoperative Photodynamic Therapy (PDT) System for Lung Cancer An intraoperative photodynamic therapy platform that uses light-activated agents and a proprietary light delivery / dosimetry system to selectively destroy malignant tissue during lung cancer surgery. It is intended for thoracic surgeons and surgical oncologists at hospitals and cancer centers performing lung resections.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Theralase Technologies: Canadian developer of photodynamic compounds (e.g., TLD-1433) and associated laser delivery systems for oncology indications. Directly comparable as a small-cap PDT platform combining a proprietary photosensitizer with a light-delivery device, though primarily focused on non-muscle-invasive bladder cancer rather than lung.
• Pinnacle Biologics: Specialty oncology company commercializing Photofrin (porfimer sodium) PDT for esophageal and lung indications. Closest direct competitor from a clinical and indication standpoint, given its PDT use in lung and aerodigestive cancers.
• Photocure ASA: Norway-based specialty pharma commercializing PDT products (e.g., Hexvix/Cysview for bladder cancer). Comparable as a focused PDT-driven oncology company that pairs a photosensitizer with a procedural light-delivery workflow.
• Steba Biotech: Private biotech advancing Tookad (padeliporfin), a vascular-targeted PDT agent used in focal therapy for prostate cancer. Directly comparable as a developer of an intra-procedural PDT regimen with paired light-delivery logistics and surgical-channel adoption.

Broad incumbents

• AngioDynamics: US medical-technology company with an interventional oncology portfolio (microwave ablation, nano-knife, thrombolytics). Comparable as a player selling procedural oncology devices into the same surgical/interventional channels that an intraoperative lung-cancer PDT would target.
• Boston Scientific: Diversified medical-device major with a sizable interventional oncology and pulmonary franchise (formerly BTG). Comparable as the large incumbent that controls many of the hospital accounts and interventional suites where a new intraoperative lung-cancer therapy would need to be adopted.
• Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology hardware and software, including image-guided and stereotactic body radiotherapy for lung cancer. Comparable as an incumbent addressing the same lung-cancer treatment paradigm with a different but overlapping intra-procedural delivery model.
• Sirtex Medical: Developer of SIR-Spheres Y-90 resin microspheres for interventional oncology in liver and other tumors. Comparable as a procedure-based oncology therapy that depends on intra-procedural delivery and interventional-radiology channel adoption.

Others

• Merck & Co. (Keytruda program): Pharmaceutical major whose anti-PD-1 therapy Keytruda is a dominant first-line option in NSCLC and is now extending into peri-operative settings. Relevant as the primary standard-of-care competitor shaping the treatment landscape Lumeda must displace or complement.
• AstraZeneca: Major oncology player with both Tagrisso (EGFR-mutant NSCLC) and a broad immuno-oncology franchise (Imfinzi, tremelimumab). Relevant as a setting-defining competitor in lung cancer that any new intraoperative modality will need to position against for guideline inclusion and payer coverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/lumeda-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumeda